Notice of Rulemaking Without Public Hearing

The Controlled Substance Board will adopt the attached rule creating CSB 2.87 relating to Scheduling Embutramide, without public hearing under the procedure set forth in s. 961.11(4), Stats.

Submittal of Written Comments

Comments may be submitted to Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, WI 53708-8366, or by email to DSPSAdminRules@wisconsin.gov. Comments must be received on or before July 15, 2022 to be included in the record of rule-making proceedings.

Initial Regulatory Flexibility Analysis

The proposed rule will not have an effect on small businesses, as defined under s. 227.114 (1).

Agency Small Business Regulatory Coordinator

Daniel Hereth, (608) 267-2435, Daniel.Hereth@wisconsin.gov
STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING : PROPOSED ORDER OF THE
PROCEEDINGS BEFORE THE : CONTROLLED SUBSTANCES BOARD
CONTROLLED SUBSTANCES BOARD : ADOPTING RULES
: (CLEARINGHOUSE RULE )

---------------------------------------------------------------------------------------------------------------------

PROPOSED ORDER

An order of the Controlled Substances Board to create CSB 2.87 relating to scheduling Embutramide.

Analysis prepared by the Department of Safety and Professional Services.

---------------------------------------------------------------------------------------------------------------------

ANALYSIS

Statutes interpreted:  s. 961.16, Stats.

Statutory authority:  s. 961.11 (1) and (4), Stats.

Explanation of agency authority:
Section 961.11 (1), Stats. provides that “[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227.”

Section 961.11(4), Stats. provides that “[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30–day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2).”

Related statute or rule:  s. 961.16, Stats.
Summary of, and comparison with, existing or proposed federal regulation:
On August 29, 2006, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing Embutramide into schedule III of the federal Controlled Substances Act. The scheduling action is effective September 28, 2006.

Plain language analysis:
This rule schedules Embutramide as a Schedule III controlled substance.

The Controlled Substances Board did not receive an objection to similarly listing Embutramide as a schedule III under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing Embutramide as a schedule III controlled substance.

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Embutramide under chapter 961, Stats. by creating the following:

CSB 2.87 Addition of Embutramide to schedule III. Section 961.18 (3) (bm), Stats., is created to read:

961.18 (3) (bm) Embutramide.

The Affirmative Action order, dated July 9, 2021, took effect on July 19, 2021, when it was published in the Administrative Register and expires upon promulgation of a final rule.

Summary of public comments received on statement of scope and a description of how and to what extent those comments and feedback were taken into account in drafting the proposed rule: N/A

Comparison with rules in adjacent states:
Illinois: Illinois has not scheduled Embutramide as a controlled substance.

Iowa: Iowa has listed Embutramide as a schedule III controlled substance [Iowa Administrative Code 124.208 (3) (n)].

Michigan: Michigan has not scheduled Embutramide as a controlled substance.

Minnesota: Minnesota has listed Embutramide as a schedule III controlled substance [Minnesota Statutes 152.02 (4) (c) (5) (x)].

Summary of factual data and analytical methodologies:
The methodology was to schedule Embutramide to conform with the federal Controlled Substances Act.

Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:
The proposed rules were posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals. No comments were received.

**Fiscal Estimate:**
The Fiscal Estimate and Economic Impact Analysis is attached.

**Effect on small business:**
These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department’s Regulatory Review Coordinator may be contacted by email at Daniel.Hereth@wisconsin.gov, or by calling (608) 267-2435.

**Agency contact person:**
Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, Wisconsin 53708; telephone 608-267-7139; email at DSPSAdminRules@wisconsin.gov.

**Place where comments are to be submitted and deadline for submission:**
Comments may be submitted to Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, Madison, WI 53708-8366, or by email to DSPSAdminRules@wisconsin.gov. Comments must be received by July 15, 2022 to be included in the record of rulemaking proceedings.

---------------------------------------------------------------------------------------------------------------------

**TEXT OF RULE**

**SECTION 1.** CSB 2.87 is created to read:

**CSB 2.87 Addition of Embutramide to schedule III.** Section 961.18 (3) (bm), Stats., is created to read:

961.18 (3) (bm) Embutramide.

**SECTION 2.** EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

---------------------------------------------------------------------------------------------------------------------

(END OF TEXT OF RULE)

---------------------------------------------------------------------------------------------------------------------
ADMINISTRATIVE RULES
Fiscal Estimate & Economic Impact Analysis

1. Type of Estimate and Analysis
☑ Original  ☐ Updated  ☐ Corrected

2. Date
04/20/22

3. Administrative Rule Chapter, Title and Number (and Clearinghouse Number if applicable)
CSB 2.87

4. Subject
Scheduling Embutramide

5. Fund Sources Affected
☐ GPR  ☐ FED  ☐ PRO  ☐ PRS  ☐ SEG  ☐ SEG-S

6. Chapter 20, Stats. Appropriations Affected

7. Fiscal Effect of Implementing the Rule
☐ No Fiscal Effect  ☐ Increase Existing Revenues  ☐ Increase Costs  ☐ Decrease Costs
☐ Indeterminate  ☐ Decrease Existing Revenues  ☐ Could Absorb Within Agency's Budget

8. The Rule Will Impact the Following (Check All That Apply)
☐ State's Economy  ☐ Specific Businesses/Sectors
☐ Local Government Units  ☐ Public Utility Rate Payers
☐ Small Businesses (if checked, complete Attachment A)

$0

10. Would Implementation and Compliance Costs Businesses, Local Governmental Units and Individuals Be $10 Million or more Over Any 2-year Period, per s. 227.137(3)(b)(2)?
☐ Yes  ☑ No

11. Policy Problem Addressed by the Rule
On August 29, 2006, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing Embutramide into schedule III of the federal Controlled Substances Act.

12. Summary of the Businesses, Business Sectors, Associations Representing Business, Local Governmental Units, and Individuals that may be Affected by the Proposed Rule that were Contacted for Comments.
The proposed rules were posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals. No comments were received.

13. Identify the Local Governmental Units that Participated in the Development of this EIA.
None.

14. Summary of Rule’s Economic and Fiscal Impact on Specific Businesses, Business Sectors, Public Utility Rate Payers, Local Governmental Units and the State’s Economy as a Whole (Include Implementation and Compliance Costs Expected to be Incurred)
None.

15. Benefits of Implementing the Rule and Alternative(s) to Implementing the Rule
The benefit is that the federal and state controlled substances acts will be uniform to avoid confusion. In addition it is in the best interest of Wisconsin citizens to schedule Embutramide as a controlled substance.

16. Long Range Implications of Implementing the Rule
The long range implications of implementing the rule will be to schedule Embutramide as a schedule III controlled substance.

17. Compare With Approaches Being Used by Federal Government
The federal government has scheduled Embutramide as a schedule III controlled substance.

18. Compare With Approaches Being Used by Neighboring States (Illinois, Iowa, Michigan and Minnesota)
Illinois: Illinois has not scheduled Embutramide as a controlled substance.

Iowa: Iowa has listed Embutramide as a schedule III controlled substance [Iowa Administrative Code 124.208 (3) (n)].
Michigan: Michigan has not scheduled Embutramide as a controlled substance.

Minnesota: Minnesota has listed Embutramide as a schedule III controlled substance [Minnesota Statutes 152.02 (4) (c) (5) (x)].

<table>
<thead>
<tr>
<th>19. Contact Name</th>
<th>20. Contact Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nilajah Hardin, Adminstrative Rules Coordinator</td>
<td>608-267-7139</td>
</tr>
</tbody>
</table>

This document can be made available in alternate formats to individuals with disabilities upon request.
1. Summary of Rule’s Economic and Fiscal Impact on Small Businesses (Separately for each Small Business Sector, Include Implementation and Compliance Costs Expected to be Incurred)

2. Summary of the data sources used to measure the Rule’s impact on Small Businesses

3. Did the agency consider the following methods to reduce the impact of the Rule on Small Businesses?
   - Less Stringent Compliance or Reporting Requirements
   - Less Stringent Schedules or Deadlines for Compliance or Reporting
   - Consolidation or Simplification of Reporting Requirements
   - Establishment of performance standards in lieu of Design or Operational Standards
   - Exemption of Small Businesses from some or all requirements
   - Other, describe:

4. Describe the methods incorporated into the Rule that will reduce its impact on Small Businesses


6. Did the Agency prepare a Cost Benefit Analysis (if Yes, attach to form)
   - Yes
   - No